Posted On: 06/18/2015 11:18:27 AM
Post# of 30066
Raised $315M
Axovant Sciences prices IPO at $15, the high end of the range
Read more: http://www.nasdaq.com/article/axovant-science...z3dQXQ85jc
Axovant Sciences, a newly formed biotech developing a late-stage Alzheimer's therapy acquired from GSK, raised $315 million by offering 21 million shares at $15, the high end of the range of $13 to $15. Axovant Sciences plans to list on the NYSE under the symbol AXON. Axovant Sciences initially filed confidentially on 3/24/2015. Jefferies & Co., Evercore Partners and RBC Capital Markets acted as lead managers on the deal.
Read more: http://www.nasdaq.com/article/axovant-science...z3dQW8X7I0
Quote:
AXON (Axovant) biggest Bio IPO ever last week. Pipeline very week compared to AMBS
http://investorshangout.com/post/view?id=3017023
Axovant Sciences prices IPO at $15, the high end of the range
Read more: http://www.nasdaq.com/article/axovant-science...z3dQXQ85jc
Axovant Sciences, a newly formed biotech developing a late-stage Alzheimer's therapy acquired from GSK, raised $315 million by offering 21 million shares at $15, the high end of the range of $13 to $15. Axovant Sciences plans to list on the NYSE under the symbol AXON. Axovant Sciences initially filed confidentially on 3/24/2015. Jefferies & Co., Evercore Partners and RBC Capital Markets acted as lead managers on the deal.
Read more: http://www.nasdaq.com/article/axovant-science...z3dQW8X7I0
(0)
(0)
